- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drugArgenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
- Labcorp unveils direct-to-consumer genetic health panel covering 163 genes and 100+ conditionsLabcorp announced the launch of a new direct-to-consumer test called the Marker by Labcorp Genetic Health Panel. The panel examines 163 genes to assess risk for more than 100 hereditary conditions…